Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The adjuvant-free inactivated enterovirus 71 (EV71) vaccine is a biologic candidate developed by the Jiangsu Province Centers for Disease Control and Prevention for the prevention of hand, foot, and mouth disease (HFMD). It consists of inactivated whole-virus EV71 (Vero cell-derived) viral antigens. Unlike most commercial EV71 vaccines that utilize aluminum-based adjuvants to enhance immune response, this specific formulation was evaluated in clinical trials to compare its safety and immunogenicity profile against adjuvanted versions. In a Phase 2 booster study, a 640 U adjuvant-free dose was tested in children to assess its ability to elicit neutralizing antibodies and maintain long-term immunity against EV71 infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Adjuvant-free inactivated enterovirus 71 vaccine (Jiangsu CDC).